Overview

  • Product name

    Anti-FGF 23 antibody [FGF23638]
    See all FGF 23 primary antibodies
  • Description

    Mouse monoclonal [FGF23638] to FGF 23
  • Host species

    Mouse
  • Tested applications

    Suitable for: Functional Studiesmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant full length protein corresponding to Human FGF 23.
    Database link: Q9GZV9

  • Positive control

    • Human PBL cells or brain tumors

Properties

Applications

Our Abpromise guarantee covers the use of ab190702 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Target

  • Function

    Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.
  • Tissue specificity

    Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).
  • Involvement in disease

    Defects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) [MIM:193100]. ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses.
    Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC) [MIM:211900]. HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues.
  • Sequence similarities

    Belongs to the heparin-binding growth factors family.
  • Post-translational
    modifications

    Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.
    O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.
  • Cellular localization

    Secreted. Secretion is dependent on O-glycosylation.
  • Information by UniProt
  • Database links

  • Alternative names

    • ADHR antibody
    • FGF-23 antibody
    • Fgf23 antibody
    • FGF23_HUMAN antibody
    • FGFN antibody
    • Fibroblast growth factor 23 antibody
    • Fibroblast growth factor 23 C-terminal peptide antibody
    • Fibroblast growth factor 23 precursor antibody
    • HPDR2 antibody
    • HYPF antibody
    • Phosphatonin antibody
    • PHPTC antibody
    • Tumor derived hypophosphatemia inducing factor antibody
    • Tumor-derived hypophosphatemia-inducing factor antibody
    see all

References

ab190702 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab190702.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up